Awani International
  • LIVE
  • Videos
  • US-China
  • BRICS-RT
  • ASEAN
  • West Asia
  • Shows
  • Podcast
  • BM
    EN
  • LIVE
  • Login
  • BM
    EN
  • LIVE
  • Login
Awani International
  • LIVE
  • Videos
  • US-China
  • BRICS-RT
  • ASEAN
  • West Asia
  • Shows
  • Podcast
Europe won't be 'blackmailed' by Trump tariffs, says Danish PM
Trump tells Norway he no longer feels obligation to think only of peace
Japan PM Takaichi calls Feb 8 election seeking mandate for spending plans, defence build-up
  • PRIVACY POLICY
  • TERMS OF USE
  • ADVERTISE WITH US
  • INVESTOR

Astro AWANI | Copyright © 2025 Measat Broadcast Network Systems Sdn Bhd 199201008561 (240064-A)

Merck says study shows COVID-19 drug causes quick reduction in virus

Reuters
Reuters
06/03/2021
06:59 MYT
Merck says study shows COVID-19 drug causes quick reduction in virus
The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS pic
BENGALURU: U.S. drugmaker Merck & Co Inc said on Saturday the experimental antiviral drug molnupiravir it is developing with Ridgeback Bio showed a quicker reduction in infectious virus in its phase 2a study among participants with early COVID-19.
"The secondary objective findings in this study, of a quicker decrease in infectious virus among individuals with early COVID-19 treated with molnupiravir, are promising," said William Fischer, Associate Professor of Medicine at the University of North Carolina School of Medicine, in a statement from the companies.
The antiviral is being currently tested in a Phase 2/3 trial that is set to be completed in May.
Merck decided to focus on therapeutics after its two COVID-19 vaccines failed to generate desired immune responses, prompting it to abandon the program in January.
Related Topics
#COVID-19
#merck
#drug
#study
Must-Watch Video
Stay updated with our news